Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer | Zendy

Karim Fizazi | Zendy; Neal D. Shore | Zendy; Teuvo L.J. Tammela | Zendy; Albertas Ulys | Zendy; Egils Vjaters | Zendy; S. Polyakov | Zendy; Mindaugas Jievaltas | Zendy; Murilo Luz | Zendy; B. Yа. Alekseev | Zendy; Iris Kuss | Zendy; Christian Kappeler | Zendy; Amir Snapir | Zendy; Toni Sarapohja | Zendy; Matthew R. Smith | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

Author(s) -

Karim Fizazi,

Neal D. Shore,

Teuvo L.J. Tammela,

Albertas Ulys,

Egils Vjaters,

S. Polyakov,

Mindaugas Jievaltas,

Murilo Luz,

B. Yа. Alekseev,

Iris Kuss,

Christian Kappeler,

Amir Snapir,

Toni Sarapohja,

Matthew R. Smith

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1815671

Subject(s) - prostate cancer , medicine , castration , oncology , cancer , androgen deprivation therapy , metastasis , androgen receptor , prostate , orchiectomy , androgen , hormone

Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. We evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research